Payman Khales Assumes Role as Integer President and CEO
Integer (NYSE: ITGR) announced that Payman Khales has assumed the role of President and Chief Executive Officer and joined the company's Board, effective Oct 24, 2025, completing a planned transition announced in April 2025.
Khales joined Integer in 2018, doubled Cardio & Vascular sales in seven years while improving service and profitability, and most recently served as Chief Operating Officer overseeing both business units and global operations. He succeeds Joseph Dziedzic, who is retiring after eight years as CEO and will remain an advisor through Mar 31, 2026 to support the transition.
Integer (NYSE: ITGR) ha annunciato che Payman Khales ha assunto il ruolo di Presidente e Amministratore Delegato ed è entrato a far parte del consiglio di amministrazione dell'azienda, con effetto dal 24 ottobre 2025, completando una transizione pianificata annunciata nell'aprile 2025.
Khales è entrato in Integer nel 2018, ha raddoppiato le vendite di Cardio & Vascular in sette anni migliorando al contempo servizio e redditività, e nell'ultima posizione è stato Chief Operating Officer supervisionando entrambe le unità di business e le operazioni globali. Sostituisce Joseph Dziedzic, che va in pensione dopo otto anni come CEO e rimarrà consigliere fino al 31 marzo 2026 per supportare la transizione.
Integer (NYSE: ITGR) anunció que Payman Khales asumió el cargo de Presidente y Director Ejecutivo y se unió al Consejo de la compañía, con efecto a partir del 24 de octubre de 2025, completando una transición planificada anunciada en abril de 2025.
Khales se unió a Integer en 2018, duplicó las ventas de Cardio & Vascular en siete años mientras mejoraba el servicio y la rentabilidad, y más recientemente se desempeñó como Director de Operaciones supervisando ambas unidades de negocio y las operaciones globales. Reemplaza a Joseph Dziedzic, que se retira tras ocho años como CEO y permanecerá como asesor hasta el 31 de marzo de 2026 para apoyar la transición.
Integer (NYSE: ITGR)가 Payman Khales가 회장 겸 최고경영자(CEO)로 취임하고 이사회에 합류했다고 발표했으며, 2025년 10월 24일부로 발효되며 2025년 4월에 발표된 계획된 전환을 완료합니다.
Khales는 2018년 Integer에 합류하여 7년간 Cardio & Vascular 매출을 두 배로 늘리면서 서비스와 수익성을 개선했고, 최근에는 Chief Operating Officer로서 두 사업부와 글로벌 운영을 감독했습니다. 그는 8년간 CEO로 재직한 Joseph Dziedzic의 뒤를 이어 전환 지원을 위해 2026년 3월 31일까지 자문역으로 남게 됩니다.
Integer (NYSE: ITGR) a annoncé que Payman Khales a pris les fonctions de Président-directeur général et a rejoint le conseil d'administration de l'entreprise, à compter du 24 octobre 2025, complétant une transition planifiée annoncée en avril 2025.
Khales a rejoint Integer en 2018, a doublé les ventes Cardio & Vascular en sept ans tout en améliorant le service et la rentabilité, et a occupé récemment le poste de Chief Operating Officer supervisant les deux unités commerciales et les opérations mondiales. Il succède à Joseph Dziedzic, qui prend sa retraite après huit ans en tant que PDG et restera conseiller jusqu'au 31 mars 2026 pour soutenir la transition.
Integer (NYSE: ITGR) gab bekannt, dass Payman Khales die Position des Präsidenten und Chief Executive Officer übernommen hat und dem Vorstand des Unternehmens beigetreten ist, mit Wirkung zum 24. Oktober 2025 und damit der geplanten im April 2025 angekündigten Übergabe abgeschlossen.
Khales trat 2018 bei Integer ein, verdoppelte den Umsatz von Cardio & Vascular in sieben Jahren und verbesserte gleichzeitig Service und Rentabilität, und diente zuletzt als Chief Operating Officer und beaufsichtigte beide Geschäftsbereiche sowie weltweite Operationen. Er folgt auf Joseph Dziedzic, der nach acht Jahren als CEO in den Ruhestand geht und bis zum 31. März 2026 als Berater verbleiben wird, um den Übergang zu unterstützen.
Integer (NYSE: ITGR) أعلن أن Payman Khales قد تولى منصب رئيس مجلس الإدارة والمدير التنفيذي وانضم إلى مجلس إدارة الشركة، اعتباراً من 24 أكتوبر 2025، مكتملًا انتقالاً مخططًا له أعلن عنه في أبريل 2025.
انضم Khales إلى Integer في 2018، ضاعف مبيعات Cardio & Vascular خلال سبع سنوات مع تحسين الخدمة والربحية، وكان مؤخرًا يشغل منصب رئيس العمليات الإشرافي على كل من وحدتي الأعمال والعمليات العالمية. يحل محل Joseph Dziedzic، الذي يتقاعد بعد eight سنوات كـCEO وسيظل مستشارًا حتى 31 مارس 2026لدعم الانتقال.
- Sales doubled in Cardio & Vascular under Khales over seven years
- Effective CEO start date: Oct 24, 2025; also joined the Board
- Operational experience: served as COO overseeing both business units and global operations
- Longtime CEO departing: Joseph Dziedzic retires after eight years (advising through Mar 31, 2026)
Insights
Internal CEO succession completed; continuity and operational track record lower near‑term execution risk.
Integer executed a planned leadership transition on
The main dependencies are integration of strategy at the top level and retention of key customer relationships. The announcement cites prior performance: doubling sales in seven years and above‑market growth under his business leadership; those facts support credibility but do not guarantee company‑wide outcomes. Watch near‑term leadership execution, any shifts in strategic priorities, and advisory support through
~ Planned Leadership Transition Completed ~
PLANO, Texas, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading global medical device contract development and manufacturing organization (CDMO), today shared that, as part of a planned transition originally announced in April 2025, Payman Khales has assumed the role of President and Chief Executive Officer. He also joins the company’s Board of Directors. He succeeds Joseph Dziedzic, who is retiring after eight years of distinguished service as Integer President and CEO and will continue to serve as an advisor through March 31, 2026, to support a smooth transition.
Mr. Khales joined Integer in 2018 as President of the Cardio & Vascular business, where he led a successful market- and customer-focused strategy, doubling sales in seven years and driving above-market growth, while further improving service levels and profitability. Most recently, as Chief Operating Officer, he oversaw both of Integer’s business units and its global operations, further strengthening Integer’s reputation as a strategic partner to medical device companies and OEMs worldwide.
“It is a privilege to step into the role of CEO at Integer,” said Mr. Khales. “I am energized by the opportunities ahead as we continue to advance our strategy. Together with our talented associates, we will create value by innovating, collaborating with our customers, and delivering life-changing medical technologies to patients around the world. I am grateful to Joe for his mentorship and support, and I look forward to leading Integer.”
Prior to joining Integer, Mr. Khales held senior leadership roles at CECO Environmental Corp. and Ingersoll Rand Company. He holds an Executive MBA from Indiana University’s Kelley School of Business and a Bachelor of Science in Mechanical Engineering from École Polytechnique de Montréal.
About Integer®
Integer Holdings Corporation (NYSE: ITGR) is one of the largest medical device contract development and manufacturing organizations (CDMO) in the world, serving the cardiac rhythm management, neuromodulation, and cardio and vascular markets. As a strategic partner of choice to medical device companies and OEMs, Integer is committed to enhancing the lives of patients worldwide by providing innovative, high-quality products and solutions. The Company’s brands include Greatbatch Medical® and Lake Region Medical®. Additional information is available at www.integer.net.
| Investor Relations: | Media Relations: |
| Kristen Stewart | Lauren Ban |
| kristen.stewart@integer.net | lauren.ban@integer.net |
| 551.337.3973 | 469.476.9615 |
FAQ
When did Payman Khales become CEO of Integer (ITGR)?
What role will Joseph Dziedzic have after stepping down as Integer CEO (ITGR)?
What track record did Payman Khales have at Integer before becoming CEO (ITGR)?
Does the CEO transition at Integer (ITGR) follow a prior announcement?
What are Payman Khales's educational credentials mentioned for Integer (ITGR)?
